No video

ADA 2021 - SURPASS-2: Tirzepatide versus semaglutide in type 2 diabetes | Juan Pablo Frías

  Рет қаралды 10,302

Medicine Matters diabetes

Medicine Matters diabetes

3 жыл бұрын

Juan Pablo Frías explains the significance of the SURPASS-2 findings, in which the dual agonist tirzepatide provided superior glycemic control and weight loss to semaglutide (5:44).
View more on Medicine Matters diabetes: bit.ly/3gRSoyi

Пікірлер
Interpreting the Data with Tirzepatide
16:45
Cardiometabolic Health Congress (CMHC)
Рет қаралды 6 М.
Идеально повторил? Хотите вторую часть?
00:13
⚡️КАН АНДРЕЙ⚡️
Рет қаралды 18 МЛН
Kids' Guide to Fire Safety: Essential Lessons #shorts
00:34
Fabiosa Animated
Рет қаралды 15 МЛН
Bony Just Wants To Take A Shower #animation
00:10
GREEN MAX
Рет қаралды 7 МЛН
WEGOVY: What You Didn’t Know!  Endocrinologist Explains
16:08
Semaglutide and Tirzepatide Revolution On Weight Loss
33:25
VBoutique Aesthetics & Wellness
Рет қаралды 2,5 М.
STEP 4: Long-term semaglutide treatment combats weight regain | Domenica Rubino
6:00
Medicine Matters diabetes
Рет қаралды 15 М.
Dr Jason Fung’s BRUTALLY Honest Opinion On OZEMPIC!
12:33
The Diary Of A CEO Clips
Рет қаралды 1,6 МЛН
The skinny on Ozempic, Wegovy, Mounjaro, and Trulicity.
32:54
CardioVisual
Рет қаралды 16 М.
The American Diabetes Association’s Standards of Care in Diabetes-2024
57:25
American Diabetes Association
Рет қаралды 11 М.